Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 36

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 36
---
                                                    
 and retain enough talented employees;                                                                                      |
| ● | manage                                                                                                                     
 its clinical trials effectively;                                                                                           |
| ● | manage                                                                                                                     
 its external manufacturing operations with contract research organizations effectively and in a cost-effective manner; and |
| ● | manage                                                                                                                     
 its development efforts effectively while carrying out its contractual obligations to contractors and other third parties. |

In addition, TELI may utilize the services of part-time outside consultants and contractors to perform several tasks for it, including tasks related to compliance programs, clinical trial management, regulatory affairs, formulation development and other drug development functions. Its growth strategy may entail expanding its use of consultants and contractors to implement these and other tasks going forward. If TELI is not able to effectively expand its organization by hiring new employees and expanding its consultants and contractors, it may be unable to successfully implement the tasks necessary to effectively execute on its planned research, development, manufacturing, and commercialization activities and, accordingly, may not achieve its research, development and commercialization goals.

| 19 |

Risks Related to the Merger

Following the Merger, the TELI shareholders may potentially own a majority of TELO.

Following the issuance of the Merger
Share Consideration and Warrants, at the Closing, pre-Merger holders of TELI may potentially own a majority of the post-Merger TELO shares.
Accordingly, after the completion of the Merger, the current stockholders of TELI will own a smaller percentage of the post-Merger combined
company than their ownership of their respective companies prior to the Merger. Immediately after the Merger, TELO securityholders as
of immediately prior to the Merger are currently estimated to own approximately 41% of the outstanding shares of the post-Merger company
on a fully-diluted basis and former TELI securityholders are currently estimated to own approximately 59% of the outstanding shares of
the combined post-Merger company on a fully-diluted basis.

TELO stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger,

If the post-Merger company is unable
to realize the full strategic and financial benefits currently anticipated from the Merger, TELI stockholders will have experienced substantial
dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit
to the extent the combined company is able